All In Biotech

Drug Trial Radar · NCT01278173

A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)

A Prospective, Open-label Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)

Last checked: Nov 19, 2026Latest source record: Jun 7, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

65

Actual

Start

Dec 2010

Primary completion

May 2015

Study completion May 2015

Sponsor

Lead sponsor
Lundbeck LLCIndustry
Sponsor type
Industry
First posted
Jan 17, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Supportive care
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the change in visual fields by means of automated static perimetry and to evaluate the change in retinal structure by means of spectral domain optical coherence tomography (SD-OCT) in adult patients with refractory complex partial seizures (CPS) being treated with vigabatrin (Sabril®)

Conditions

  • Adult Refractory Complex Partial Seizures

Interventions

  • SabrilDrug

    Sabril: 500 mg tablets, orally. Physicians will dose their patients according to guidance provided in the product label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Reference Value in Field Width as Measured by 30-2 SITA Fast in Field Sensitivity (Mean Deviation - MD in dB)Time frame: Baseline (Month 0), Month 3, Month 6, Month 9, Month 12
  2. Change From Reference Value in Average RNFL (Retinal Nerve Fiber Layer) Thickness (µm) as Measured by SD-OCT (Spectral Domain-Optical Coherence Tomography)Time frame: Baseline (Month 0), Month 3, Month 6, Month 9, Month 12

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • California Pacific Medical Center

    San Francisco, California

  • Yale Medical Center

    New Haven, Connecticut

  • CNMRI

    Dover, Delaware

  • Sunrise Clinical Research Group

    Hollywood, Florida

  • University of South Florida

    Tampa, Florida

  • Peachtree Neurological Clinic

    Atlanta, Georgia

  • Idaho Comprehensive Epilepsy Center

    Boise, Idaho

  • OSF Saint Francis Medical Center

    Peoria, Illinois

  • University of Kentucky Lexington

    Lexington, Kentucky

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Minnesota Epilepsy Group, PA

    Saint Paul, Minnesota

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

  • Columbia University Medical Center

    New York, New York

  • Neuroscience & Spine Institute

    Charlotte, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • University of Texas

    Houston, Texas

  • Covenant Medical Group

    Lubbock, Texas

  • University of Texas Health Science Center

    San Antonio, Texas

  • Aurora BayCare Medical Center

    Green Bay, Wisconsin

  • Aurora St. Luke's Medical Center

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.